The $10 million gift from Andrew M. and Jane M. Bursky will advance cutting-edge research at the newly named Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs. Research at the center focuses on harnessing the immune system to fight cancer, infectious diseases, and autoimmune disorders.Read More
Science Market Update
Tags: Washington University in St. Louis, Washington University, Washington Univsersity St. Louis, Missouri, MO, Midwest Region, new research funding, cancer research, cancer therapy, Immune System, immune system research, infectious diseases
Chemical bioengineers find and create bacteria for several different purposes, such as eating chlorine and consuming toxic byproducts of biodiesel plants. A closer look at these bacterial communities undertaken in a study at Washington University in St. Louis shows that there is actually a division of labor between bacterial workers and layabouts.Read More
Destroying a tumor is sometimes only the beginning when it comes to fighting cancer. We’ve seen a UCLA team eradicate tumor remnants in the bloodstream and a Cincinnati researcher who developed a method to prevent breast cancer tumors from leaving behind stem cells from which they could regenerate. Now a team at Washington University in St. Louis has discovered a way to shut down the stem cells in the tumors of brain cancer.Read More
For some diseases, one can “carry” the disease without showing any of its symptoms. In the case of Fragile X syndrome, a cause of autism and intellectual disability, there’s no such concept. However, researchers at Washington University at St. Louis are working on a way to reduce these carrier symptoms.Read More
Researchers at Washington University in St. Louis have received an immense amount of additional funding from the National Institute on Aging to assist them on the first large-scale clinical trial to study Alzheimer's disease that is underway. This clinical trial, called the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) will work with people who have dominantly inherited forms of Alzheimer's to identify new drugs that can slow the onset of the disease, or stop it altogether.
Beginning with $5.5 million in funding this year, the trial will continue to receive funding from the NIH over the next five years to total $26 million. The National Institute of Aging has been supporting this research since 2012, when the project began. This new funding will allow the trial to add an additional 300-400 participants to the study, as well as assist the research team in adding new drugs to the study. The trial is being run in locations in the United States, Canada, Europe, and Australia, and this funding will help add 10-15 more locations.Read More